News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sunesis Pharmaceuticals, Inc. (SNSS) Announces Presentation of Adaptive Study Design for Vosaroxin Phase 3 VALOR Trial in AML at American Society of Clinical Oncology 2011 Annual Meeting



6/6/2011 11:01:19 AM

SOUTH SAN FRANCISCO, Calif., June 6, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of the adaptive study design for its Phase 3 VALOR trial of vosaroxin in acute myeloid leukemia (AML) at the Trials in Progress Poster Session of the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The poster (Poster #48G), entitled "Adaptive design of VALOR, a phase 3 trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia," is available on the Sunesis website at www.sunesis.com.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES